CD8α ALN-1 synergizes with a neovasculature-targeted tumor necrosis factor (TNF) AcTakine, leading to complete tumor destruction and formation of immunological memory that protects against secondary tumor challenge. This evidence concerns the gene CD8A and neoplasm.